[go: up one dir, main page]

PE20160027A1 - Composiciones y metodos de construcciones quimericas del virus del dengue en vacunas - Google Patents

Composiciones y metodos de construcciones quimericas del virus del dengue en vacunas

Info

Publication number
PE20160027A1
PE20160027A1 PE2015001953A PE2015001953A PE20160027A1 PE 20160027 A1 PE20160027 A1 PE 20160027A1 PE 2015001953 A PE2015001953 A PE 2015001953A PE 2015001953 A PE2015001953 A PE 2015001953A PE 20160027 A1 PE20160027 A1 PE 20160027A1
Authority
PE
Peru
Prior art keywords
dengue virus
compositions
dengue
constructs
virus
Prior art date
Application number
PE2015001953A
Other languages
English (en)
Inventor
Claire Kinney
Richard M Kinney
Jill A Livengood
Dan T Stinchcomb
Original Assignee
Takeda Vaccines Inc
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Vaccines Inc, Us Gov Health & Human Serv filed Critical Takeda Vaccines Inc
Publication of PE20160027A1 publication Critical patent/PE20160027A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C07K14/1816—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus), border disease virus
    • C07K14/1825—Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C12N15/8613—Chimaeric vector systems comprising heterologous sequences for production of another viral vector
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24141—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24162—Methods of inactivation or attenuation by genetic engineering
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invencion se refiere a composiciones, usos y manufactura de construcciones del virus del dengue y virus del vengue vivos atenuados. En ciertas modalidades, la composicion puede incluir, pero no se limita a una composicion tetravalente del virus del dengue. En ciertas modalidades, las composiciones pueden incluir construcciones de uno o mas serotipos del virus del dengue, tales como las construcciones del virus dengue-1 (DEN-1), el virus dengue-2 (DEN-2), los virus dengue-3 (DEN 3) o dengue-4 (DEN-4). En otras modalidades, las construcciones descritas en esta invencion pueden combinarse en una composicion para generar una vacuna contra una o mas construcciones de virus del dengue que pueden o no ser subsecuentemente pasadas a celulas de mamiferos
PE2015001953A 2013-03-15 2014-03-12 Composiciones y metodos de construcciones quimericas del virus del dengue en vacunas PE20160027A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361800204P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
PE20160027A1 true PE20160027A1 (es) 2016-01-28

Family

ID=50678274

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2021000217A PE20211814A1 (es) 2013-03-15 2014-03-12 Composiciones y metodos de construcciones quimericas del virus del dengue en vacunas
PE2015001953A PE20160027A1 (es) 2013-03-15 2014-03-12 Composiciones y metodos de construcciones quimericas del virus del dengue en vacunas

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2021000217A PE20211814A1 (es) 2013-03-15 2014-03-12 Composiciones y metodos de construcciones quimericas del virus del dengue en vacunas

Country Status (32)

Country Link
US (6) US9783579B2 (es)
EP (5) EP4129330B1 (es)
JP (2) JP6818548B2 (es)
KR (4) KR102389908B1 (es)
CN (5) CN111778263B (es)
AR (4) AR095598A1 (es)
AU (2) AU2014235476B2 (es)
CA (4) CA3166063A1 (es)
CR (1) CR20150569A (es)
DK (1) DK4129330T5 (es)
DO (1) DOP2015000232A (es)
EC (1) ECSP23013715A (es)
ES (2) ES2933970T3 (es)
FI (2) FI3539565T3 (es)
FR (1) FR22C1064I2 (es)
HR (1) HRP20231581T1 (es)
HU (2) HUE061507T2 (es)
LT (2) LT4129330T (es)
MX (5) MX374519B (es)
MY (1) MY187796A (es)
NL (1) NL301223I2 (es)
NO (1) NO2023026I1 (es)
NZ (1) NZ630869A (es)
PE (2) PE20211814A1 (es)
PH (1) PH12015502120B1 (es)
PL (1) PL3539565T3 (es)
PT (1) PT3539565T (es)
SG (3) SG10201913387XA (es)
SI (1) SI4129330T1 (es)
TW (3) TWI726312B (es)
UY (1) UY35489A (es)
WO (1) WO2014150939A2 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6818548B2 (ja) * 2013-03-15 2021-01-20 タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. ワクチンにおけるデングウイルスキメラ構築物に関する組成物および方法
US10004795B2 (en) * 2015-09-08 2018-06-26 Fundacao Butantan Process for preparing an attenuated tetravalent dengue vaccine
CN108699534B (zh) * 2015-11-27 2022-05-24 Km生物医药股份公司 具有登革热病毒减毒株库的活病毒和包含其作为抗原的登革热疫苗
US11007261B2 (en) * 2016-04-13 2021-05-18 Takeda Vaccines, Inc. Compositions and methods of vaccination against dengue virus in children and young adults
US11426461B2 (en) 2018-09-05 2022-08-30 Takeda Vaccines, Inc. Methods for preventing dengue and hepatitis A
BR112021003962A2 (pt) 2018-09-05 2021-05-25 Takeda Vaccines, Inc. dose unitária de vacina contra dengue e sua administração
US11464815B2 (en) 2018-09-05 2022-10-11 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
BR112022015710A2 (pt) 2020-02-27 2022-09-27 Takeda Vaccines Inc Método para remover dna de célula hospedeira a partir da preparação de vírus
WO2021173597A1 (en) * 2020-02-28 2021-09-02 Merck Sharp & Dohme Corp. Dengue serotype specific rt-pcr multiplex assay
EP3892737A1 (en) * 2020-04-09 2021-10-13 Takeda Vaccines, Inc. Qualitative and quantitative determination of single virus haplotypes in complex samples
WO2023147337A2 (en) 2022-01-25 2023-08-03 Takeda Vaccines, Inc. Large-scale flaviviral vaccine production and manufacture
EP4479025B1 (en) 2022-02-15 2026-02-04 Takeda Vaccines, Inc. Dengue vaccine batch mixing process
WO2023215383A1 (en) 2022-05-04 2023-11-09 Takeda Vaccines, Inc. Computer-based determination of flavivirus infectivity
EP4357464A1 (en) * 2022-10-20 2024-04-24 Takeda Vaccines, Inc. A method for detecting the presence of a dengue virus serotype in a sample containing at least one dengue virus serotype
WO2024108087A1 (en) 2022-11-18 2024-05-23 Takeda Vaccines, Inc. A method for determining the proportion of a live, attenuated flavivirus having a nucleotide sequence comprising at least one attenuation locus in a formulation
CN120529951A (zh) 2022-11-29 2025-08-22 武田疫苗股份有限公司 大规模黄病毒疫苗生产和制造
WO2025122855A1 (en) 2023-12-08 2025-06-12 Takeda Vaccines, Inc. A method for determining the concentration of residual vero cell genomic dna in a sample containing virus obtained from production in vero cells

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5276941A (en) 1975-12-23 1977-06-28 Ito Masato Method of conversing infrared rays
US4810092A (en) 1986-02-21 1989-03-07 Midac Corporation Economical spectrometer unit having simplified structure
JPH0768267B2 (ja) 1986-06-05 1995-07-26 財団法人阪大微生物病研究会 フラビウイルス抗原
JPH084508B2 (ja) 1987-09-16 1996-01-24 国立予防衛生研究所長 組み換えワクチニアウイルス
JP2511494B2 (ja) 1988-05-12 1996-06-26 善治 松浦 日本脳炎ウイルス表面抗原蛋白質の製造法
US6184024B1 (en) 1988-07-14 2001-02-06 The United States Of America As Represented By The Department Of Health And Human Services Chimeric and/or growth-restricted flaviviruses
IL91304A0 (en) 1988-08-20 1990-03-19 Us Health Recombinant vaccinia virus for prevention of disease caused by flavivirus
US5514375A (en) 1990-08-15 1996-05-07 Virogenetics Corporation Flavivirus recombinant poxvirus vaccine
MY109299A (en) 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
US5494671A (en) 1990-08-27 1996-02-27 The United States Of America As Represented By The Department Of Health And Human Services C-terminally truncated dengue and Japanese encephalitis virus envelope proteins
DK0604566T3 (da) 1991-09-19 2000-04-10 Us Health Kimærisk og/eller vækstbegrænsede flavivirus
JPH05276941A (ja) 1992-02-28 1993-10-26 Nippon Zeon Co Ltd フラビウイルス科に属するウイルスの表面抗原タンパク質を含む非感染性の構造物粒子の製造方法
CA2224724C (en) 1995-05-24 2007-12-04 Hawaii Biotechnology Group, Inc. Subunit vaccine against flavivirus infection
AU6093296A (en) * 1995-06-07 1996-12-30 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Infectious dengue 2 virus pdk-53 as quadravalent vaccine
PL192957B1 (pl) 1997-02-28 2006-12-29 Acambis Inc Chimeryczny żywy, zakaźny, atenuowany wirus, jego zastosowanie oraz cząsteczka kwasu nukleinowego kodująca chimeryczny żywy, zakaźny, atenuowany wirus
DE69833002T2 (de) 1997-10-08 2006-08-24 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Chimärer impfstoff gegen das zeckenenzephalitis virus
IL139844A0 (en) 1998-06-04 2002-02-10 Us Gov Health & Human Serv Nucleic acid vaccines for prevention of flavivirus infection
DE29810020U1 (de) 1998-06-04 1998-09-24 Siemens AG, 80333 München Kunststoffbehälter zur Tieftemperaturlagerung von biologischen Materialien
AU1813901A (en) * 1999-12-01 2001-06-12 Oravax, Inc Chimeric flavivirus vaccines
AU2001238441B2 (en) * 2000-02-16 2006-10-26 Mahidol University Avirulent, immunogenic flavivirus chimeras
ATE412738T1 (de) * 2000-05-30 2008-11-15 Univ Mahidol Attenuierte stammen von denguevirus und ihre verwendungen in impfstoffzusammensetzungen
EP1372711A4 (en) 2001-03-12 2005-06-01 Univ Yale COMPOSITIONS AND METHODS OF WEST NIL VIRUS POLYPEPTIDES
KR20080018271A (ko) * 2005-06-17 2008-02-27 사노피 파스퇴르 약독화된 뎅기 혈청형 2 균주
MX2007015873A (es) * 2005-06-17 2008-04-22 Sanofi Pasteur Cepa atenuada de virus de dengue serotipo 1.
KR20070017759A (ko) 2005-08-08 2007-02-13 삼성전자주식회사 초해상 정보 저장 매체, 기록/재생 장치 및 기록/재생 방법
BRPI0614265A2 (pt) * 2005-08-10 2011-03-22 Acambis Inc uso de uma vacina do vìrus da febre amarela e de uma vacina de flavivìrus quimérico e kit contendo referidas vacinas
US7968102B2 (en) * 2006-01-13 2011-06-28 Sanofi Pasteur S.A. Dengue chimeric viruses
DK2589602T3 (en) * 2006-08-15 2016-07-25 The Government Of The U S A As Repr By The Secretary Dept Of Health & Human Services The Nat Inst Of Development of dengue virus vaccine components
AU2008311220B2 (en) 2007-07-13 2013-10-03 Florida Gulf Coast University Board Of Trustees Optimized dengue virus entry inhibitory peptide (DN81)
US8715689B2 (en) * 2008-04-30 2014-05-06 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Chimeric west nile/dengue viruses
SG157244A1 (en) 2008-05-15 2009-12-29 Mp Biomedicals Asia Pacific Pte Ltd Point of care test for the detection of exposure or immunity to dengue virus
WO2010085358A2 (en) * 2009-01-23 2010-07-29 The Board Of Regents Of The University Of Texas System Flaviviruses expressing the prm, e, and ns1 proteins of other flaviviruses and uses thereof
US8968996B2 (en) 2009-06-01 2015-03-03 Takeda Vaccines, Inc. Compositions and methods for rapid immunization against dengue virus
NZ597000A (en) 2009-06-01 2014-07-25 Takeda Vaccines Inc Compositions and methods for administration of vaccines against dengue virus
CN101560520A (zh) * 2009-06-04 2009-10-21 中国疾病预防控制中心病毒病预防控制所 乙脑/登革嵌合病毒及其应用
BRPI0904020B8 (pt) * 2009-10-01 2021-05-25 Fundacao Oswaldo Cruz composição vacinal contra o vírus da dengue, e, kit
EP2353609A1 (en) 2010-02-04 2011-08-10 Sanofi Pasteur Immunization compositions and methods
JP2015520196A (ja) 2012-06-10 2015-07-16 タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. デングウイルスに対するワクチン投与のための組成物および方法
EP2877207A1 (en) 2012-07-24 2015-06-03 Sanofi Pasteur Vaccine compositions for prevention against dengue virus infection
US20150196631A1 (en) 2012-07-24 2015-07-16 Sanofi Pasteur Vaccine compositions
TW201920677A (zh) * 2012-11-08 2019-06-01 美商武田疫苗股份有限公司 登革熱病毒血清型４型之建構物的組成物、方法及用途
US9878031B2 (en) * 2012-12-14 2018-01-30 Takeda Vaccines, Inc. Compositions, methods of administration and uses for trivalent dengue virus formulations
JP6818548B2 (ja) 2013-03-15 2021-01-20 タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. ワクチンにおけるデングウイルスキメラ構築物に関する組成物および方法
TWI852899B (zh) 2014-09-02 2024-08-21 法商賽諾菲巴斯德公司 疫苗組合物
WO2017005654A1 (en) 2015-07-03 2017-01-12 Sanofi Pasteur Concomitant dengue, diphtheria, tetanus, whooping cough (pertussis), polio, and haemophilus influenzae type b vaccination.
WO2017005652A1 (en) 2015-07-03 2017-01-12 Sanofi Pasteur Concomitant dengue and yellow fever vaccination
US10004795B2 (en) 2015-09-08 2018-06-26 Fundacao Butantan Process for preparing an attenuated tetravalent dengue vaccine
US11007261B2 (en) * 2016-04-13 2021-05-18 Takeda Vaccines, Inc. Compositions and methods of vaccination against dengue virus in children and young adults
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
MX2020004085A (es) 2017-10-16 2020-12-03 Serum Institute Of India Pvt Ltd Composiciones de vacuna estables que comprenden inter alia un flavivirus recombinante vivo atenuado y proceso para la preparacion de las mismas.
BR112021003962A2 (pt) 2018-09-05 2021-05-25 Takeda Vaccines, Inc. dose unitária de vacina contra dengue e sua administração
US11464815B2 (en) 2018-09-05 2022-10-11 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
EP3892737A1 (en) 2020-04-09 2021-10-13 Takeda Vaccines, Inc. Qualitative and quantitative determination of single virus haplotypes in complex samples

Also Published As

Publication number Publication date
AR123702A2 (es) 2023-01-04
LTPA2024503I1 (es) 2024-03-25
US12186363B2 (en) 2025-01-07
KR102626270B1 (ko) 2024-01-19
US9783579B2 (en) 2017-10-10
AU2019216724A1 (en) 2019-09-05
UY35489A (es) 2014-10-31
US20250018006A1 (en) 2025-01-16
EP4183411A1 (en) 2023-05-24
CN113637693A (zh) 2021-11-12
AU2019216724C1 (en) 2021-08-26
BR112015023635A2 (pt) 2018-06-05
HRP20231581T1 (hr) 2024-03-15
CA2903231C (en) 2025-12-09
CA2903231A1 (en) 2014-09-25
HUS2300022I1 (hu) 2023-08-28
EP3539565A1 (en) 2019-09-18
US20220062375A1 (en) 2022-03-03
SG11201507460PA (en) 2015-10-29
PH12015502120A1 (en) 2016-01-25
EP4129330B1 (en) 2023-09-06
MX2023000353A (es) 2023-02-13
EP3689374A1 (en) 2020-08-05
HUE061507T2 (hu) 2023-07-28
MY187796A (en) 2021-10-24
EP2968516B1 (en) 2022-01-12
CN113637694B (zh) 2024-11-12
KR20240014580A (ko) 2024-02-01
FI3539565T3 (fi) 2023-04-19
ECSP23013715A (es) 2023-04-28
CN113637694A (zh) 2021-11-12
KR102775714B1 (ko) 2025-03-06
SG10201913435TA (en) 2020-03-30
AU2019216724B2 (en) 2021-03-04
NZ735336A (en) 2021-04-30
TW202144573A (zh) 2021-12-01
CR20150569A (es) 2016-04-01
TWI726312B (zh) 2021-05-01
JP2019146594A (ja) 2019-09-05
KR20250033325A (ko) 2025-03-07
LT4129330T (lt) 2023-12-27
CA3177572A1 (en) 2014-09-25
WO2014150939A3 (en) 2014-12-31
US20230181682A1 (en) 2023-06-15
SG10201913387XA (en) 2020-02-27
CN105451763A (zh) 2016-03-30
ES2933970T3 (es) 2023-02-15
US10449231B2 (en) 2019-10-22
PE20211814A1 (es) 2021-09-14
TWI894248B (zh) 2025-08-21
EP3539565B1 (en) 2023-01-11
DOP2015000232A (es) 2016-02-29
CN113637086B (zh) 2024-10-11
ES2965652T3 (es) 2024-04-16
FR22C1064I1 (fr) 2023-02-03
KR20160002780A (ko) 2016-01-08
DK4129330T3 (da) 2023-12-11
US20140302088A1 (en) 2014-10-09
AU2014235476A1 (en) 2015-09-24
CA3166063A1 (en) 2014-09-25
CN111778263B (zh) 2024-07-26
DK4129330T5 (da) 2024-07-22
NZ630869A (en) 2017-11-24
AU2014235476B2 (en) 2019-05-16
TWI733646B (zh) 2021-07-21
BR122021015502A2 (pt) 2021-12-14
BR122021015503A2 (pt) 2021-12-14
CA3177574A1 (en) 2014-09-25
US20170290884A1 (en) 2017-10-12
NL301223I2 (nl) 2023-07-26
PL3539565T3 (pl) 2023-09-25
PH12015502120B1 (en) 2024-02-16
CN113637693B (zh) 2024-10-11
AR133264A2 (es) 2025-09-10
US11931399B2 (en) 2024-03-19
US20200061151A1 (en) 2020-02-27
WO2014150939A2 (en) 2014-09-25
KR20220054892A (ko) 2022-05-03
CN113637086A (zh) 2021-11-12
EP2968516A2 (en) 2016-01-20
FR22C1064I2 (fr) 2024-12-13
JP2016513970A (ja) 2016-05-19
CN105451763B (zh) 2021-06-18
PT3539565T (pt) 2023-04-12
KR102389908B1 (ko) 2022-04-26
AR095598A1 (es) 2015-10-28
FIC20230021I1 (fi) 2023-06-27
HK1220359A1 (zh) 2017-05-05
EP4129330A1 (en) 2023-02-08
JP7050031B2 (ja) 2022-04-07
TW201516147A (zh) 2015-05-01
SI4129330T1 (sl) 2024-02-29
MX2015012893A (es) 2016-04-04
CN111778263A (zh) 2020-10-16
EP3689374B1 (en) 2022-11-02
MX374519B (es) 2025-03-06
TW201945545A (zh) 2019-12-01
BR112015023635A8 (pt) 2021-12-14
NO2023026I1 (no) 2023-07-04
MX2023000354A (es) 2023-02-13
MX2023000349A (es) 2023-04-24
MX2019003602A (es) 2022-06-27
AR132009A2 (es) 2025-05-21
JP6818548B2 (ja) 2021-01-20

Similar Documents

Publication Publication Date Title
ECSP23013715A (es) Composiciones y métodos de construcciones quiméricas del virus del dengue en vacunas
AR093421A1 (es) Composiciones, metodos y usos de construcciones de virus del dengue de serotipo-4
CO2018011355A2 (es) Composiciones y métodos de vacunación contra virus de dengue en niños y adultos jóvenes
PE20140646A1 (es) Vacuna de virus de dengue inactivado
EP2448410A4 (en) TREATMENT AND PREVENTION OF INFECTIONS WITH THE DENGUE VIRUS
MX2009010610A (es) Dominio de enlace especifico de especies cruzadas.
UY35013A (es) Composiciones farmacéuticas que contienen un antagonista de il-4r y sus usos
CU20110219A7 (es) Composiciones y métodos para administración de vacunas contra virus del dengue
MX2019010530A (es) Alfavirus recombinantes atenuados incapaces de replicarse en mosquitos y usos de estos.
PE20110992A1 (es) Composicion inmunogenica que comprende un antigeno del virus del dengue
BR112015001313A2 (pt) composições de vacina
CO6440541A2 (es) Virus de diarrea viral bovina con una proteina erns modificada
AR096863A1 (es) Composiciones de caucho natural mejoradas
MX383330B (es) Particula tipo virus de flavivirus.
ECSP18081582A (es) Constructos de alfavirus vivo atenuado y métodos y usos de los mismos
BR112018077540A2 (pt) vírus quimérico da dengue/zika como vacinas de zika vírus vivo atenuado
CO2021017772A2 (es) Virus del dengue atenuados
BR112016029201B8 (pt) Quimera de ácido nucleico, composição imunogênica, uso de um ou mais vírus inativados compreendendo a quimera de ácido nucleico e método para inativar um vírus
TH170668A (th) องค์ประกอบ และวิธีการสำหรับชุดโครงสร้างไคมีริกไวรัสเด็งกีในวัคซีน
MX350236B (es) Composiciones de peptidos para el tratamiento y diagnostico de la fiebre por virus del dengue.
CO6321231A2 (es) Imidazolil-bifenil-imidazoles como inhibidores del virus de la hepatitis c